EGFRIs)

Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
From: www.news-medical.net